Bedaquilin (1) – Sirturo®
Multidrug-resistant pulmonary tuberculosis
Characteristics
| Start date | 15.05.2014 |
|---|---|
| Resolution | 21.08.2014 |
| INN | Bedaquilin |
| Brand name | Sirturo® |
| Pharm. company | Janssen-Cilag GmbH |
| G-BA Procedure ID | D-112 |
| ATC code | J04AK05 Other drugs for treatment of tuberculosis (J04AK) |
| DDD | 86 mg O |
| Therapeutic area | Infectious diseases Tuberculosis (TB) Orphan |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Bedaquilin (5) | Sirturo® | Janssen-Cilag GmbH | Multidrug-resistant pulmonary tuberculosis | 70–100 | 100% Hint for considerable additional benefit Orphan | |
| Bedaquilin (4) | Sirturo® | Janssen-Cilag GmbH | Multidrug-resistant pulmonary tuberculosis, 5 to 11 years | 1 | 100% Hint for non-quantifiable additional benefit Orphan | |
| Bedaquilin (3) | Sirturo® | Janssen-Cilag GmbH | Multidrug-resistant pulmonary tuberculosis, 12 to < 18 years | 9–13 | 100% Hint for non-quantifiable additional benefit Orphan | |
| Bedaquilin (2) | Sirturo® | Janssen-Cilag GmbH | Multidrug-resistant pulmonary tuberculosis |
0
70–100 |
100% considerable additional benefit Orphan repealed | |
| Bedaquilin (1) | Sirturo® | Janssen-Cilag GmbH | Multidrug-resistant pulmonary tuberculosis | n.d. | discontinued Orphan |
<< List of all resolutions